The short version of REV-ERB agonist fits in a sentence. The long version — which is the one that helps — is below.
Reviewed 2026-01-15. Anything still debated is marked as such rather than presented as settled.
Pharmacokinetic data for SR9009 are limited in published literature. Some reports indicate low oral bioavailability and rapid clearance in animals, which complicates interpretation of exposure and effect. Researchers often use injected routes in preclinical work to achieve measurable systemic levels. Analytical studies rely on mass spectrometry to detect the parent compound and its metabolites. Questions about tissue distribution, active metabolites, and long-term consequences remain open. Species differences in metabolism can affect observed half-life and target engagement.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. These receptors help regulate circadian rhythms and metabolic gene expression. In laboratory experiments, SR9009 binds these receptors and alters transcription of genes involved in lipid handling, glucose metabolism, and mitochondrial function. It is not a naturally occurring compound and has no approved therapeutic use. Research interest stems from its ability to modify energy metabolism in cells and animal models.
In rodent studies, SR9009 has been reported to increase mitochondrial content in skeletal muscle and improve exercise endurance under some conditions. These findings led to popular descriptions such as an exercise mimetic, although that term oversimplifies the biology. Effects vary by dose, timing, tissue, and model. The compound's influence on circadian pathways means that time of administration can matter in experiments. Whether similar metabolic changes occur in humans remains largely unexplored in controlled published trials.
SR9009 stability depends on temperature, moisture, light, and solvent. Solid material is generally kept cool and dry, while solutions may require protection from repeated warming and cooling. Degradation can appear as color changes, precipitate, or new chromatographic peaks. Researchers should follow supplier instructions and their own stability data. Long-term storage conditions for human use have not been established because the compound lacks approved clinical formulation.
SR9009 is supplied as a solid research chemical, often in milligram quantities. Laboratories typically weigh it in a controlled environment because fine powders can disperse. Stock solutions are commonly prepared in dimethyl sulfoxide and stored in small aliquots to reduce freeze-thaw cycles. Personal protective equipment and chemical fume hoods are standard when handling unknown or potent compounds. These practices address laboratory safety rather than human use.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic small-molecule REV-ERB agonist | Not a hormone or natural product |
| Primary targets | REV-ERBα and REV-ERBβ | Nuclear receptors involved in circadian and metabolic regulation |
| Appearance | White to off-white solid | Typical for purified research samples |
| Solubility | Soluble in DMSO and ethanol; low water solubility | Laboratory solubility depends on solvent and purity |
| Common synonyms | SR9009; Stenabolic | Stenabolic is a colloquial name, not a formal chemical name |
Physicochemical behavior influences handling. SR9009 is described as a solid with limited aqueous solubility, so organic solvents such as dimethyl sulfoxide or ethanol are common in research stock solutions. Aqueous dilution can produce precipitates if the organic content is too low. Light, heat, and repeated freeze-thaw cycles may affect stability. Storage recommendations usually specify a desiccated freezer environment protected from light, but exact stability data depend on the formulation and matrix.
Detection in biological samples can be complicated by rapid metabolism and low circulating concentrations. Some studies report phase I and phase II metabolites, and analytical methods may need to target those species in addition to the parent compound. Immunoassays are not broadly available, so mass spectrometry remains the main confirmatory approach. For anti-doping testing, laboratories look for SR9009 and its metabolites using validated LC-MS methods. Open questions include how long metabolites remain detectable and how different routes of administration alter detection windows.
In laboratory settings, SR9009 is typically characterized by liquid chromatography–mass spectrometry (LC-MS) or high-performance liquid chromatography with ultraviolet detection (HPLC-UV). These methods can confirm identity and estimate purity, but they require reference standards for accurate quantification. Because SR9009 is not a licensed pharmaceutical, no harmonized pharmacopeial monograph exists. Laboratories often validate in-house methods for matrices such as plasma, urine, or cell culture media. Sample preparation may involve protein precipitation or liquid-liquid extraction before analysis.
Most published work on SR9009 consists of preclinical studies. It is widely sold as a research chemical, a category that does not imply safety, efficacy, or pharmaceutical-grade quality. Sports anti-doping organizations have listed SR9009 as a prohibited substance, and its presence in an athlete sample can lead to sanctions. Legal status differs by country; in several jurisdictions it is not approved for human consumption and may be treated as an unapproved new drug.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. It is not a steroid, peptide, or natural hormone. In scientific literature, it appears under the code SR9009 and in non-scientific contexts as Stenabolic. The compound was identified through chemical screening efforts aimed at targeting circadian clock components. Its status remains investigational, and no regulatory agency has approved it as a human medicine.
=== Major hormones === Neurokinin B (a tachykinin peptide) and kisspeptin (a neuropeptide), both present in KNDy neurons of the hypothalamus, are critical parts of the control system that switches on the release of GnRH at the start of puberty. GnRH (gonadotropin-releasing hormone) is a peptide hormone released from the hypothalamus which stimulates gonadotrope cells of the anterior pituitary. LH (luteinizing hormone) is a larger protein hormone secreted into the general circulation by gonadotrope cells of the anterior pituitary gland. The main target cells of LH are the Leydig cells of testes and the theca cells of the ovaries. LH secretion changes more dramatically with the initiation of puberty than FSH, as LH levels increase about 25-fold with the onset of puberty, compared with the 2.5-fold increase of FSH. FSH (follicle stimulating hormone) is another protein hormone secreted into the general circulation by the gonadotrope cells of the anterior pituitary. The main target cells of FSH are the ovarian follicles and the Sertoli cells and spermatogenic tissue of the testes. Testosterone is a steroid hormone produced primarily by the Leydig cells of the testes, and in lesser amounts by the theca cells of the ovaries and the adrenal cortex. Testosterone is the primary mammalian androgen and the "original" anabolic steroid. It acts on androgen receptors in responsive tissue throughout the body. Estradiol is a steroid hormone produced by aromatization of testosterone. Estradiol is the principal human estrogen and acts on estrogen receptors throughout the body.
Where L is the channel length. In FFF the retention is usually expressed in terms of the retention ratio, which is the void time t0 (emergence of a non retained tracer) divided by the retention time tr. The retention equation then becomes:
The mouth of the sand dollar is located on the bottom of its body at the center of the petal-like pattern. Unlike other urchins, the bodies of sand dollars also display secondary front-to-back bilateral symmetry with no morphological distinguishing features between males and females. The anus of sand dollars is located at the back rather than at the top as in most urchins, with many more bilateral features appearing in some species. These result from the adaptation of sand dollars, in the course of their evolution, from creatures that originally lived their lives on top of the seabed (epibenthos) to creatures that burrow beneath it (endobenthos).
Increased body temperature >38 °C (>100.4 °F) Confused or altered consciousness Excessive sweating Severely rigid muscles Autonomic imbalance The first symptoms of neuroleptic malignant syndrome are usually muscle cramps and tremors, fever, symptoms of autonomic nervous system instability such as unstable blood pressure, and sudden changes in mental status (agitation, delirium, or coma). Other possible symptoms include sweating, trouble swallowing, incontinence, and mutism. Once symptoms appear, they may progress rapidly and reach peak intensity in as little as three days. These symptoms can last anywhere from eight hours to forty days, with the median duration of symptoms, with treatment, being nine days. The median onset of symptoms is four days after initiating the offending medication, but in some cases symptoms may begin up to 30 days later. Symptoms are sometimes misinterpreted by doctors as symptoms of mental illness which can result in delayed treatment. Symptoms may also be mistaken for similarly presenting conditions such as malignant hyperthermia, serotonin syndrome, and substance intoxication from illicit drugs such as cocaine, methamphetamine, or MDMA. Neuroleptic malignant syndrome (NMS) usually presents with a "lead pipe rigidity" in which the muscles are stiffened and resistance is observed throughout the range of motion on testing. Severe cases may present as catatonia in which the person is not responsive to stimuli. The deep tendon reflexes in NMS are usually preserved whereas serotonin syndrome presents with myoclonus or hyperactive muscle reflexes.
=== Dyeing === The use of Prussian blue and other dyes (often in conjunction with bonding treatments) to "enhance" its appearance, make uniform or completely change the colour, is regarded as fraudulent by some purists, especially since some dyes may fade or rub off on the wearer. Dyes have also been used to darken the veins of turquoise.
Sources: en.wikipedia.org
== Species distribution == G6PD is widely distributed in many species from bacteria to humans. Multiple sequence alignment of over 100 known G6PDs from different organisms reveal sequence identity ranging from 30% to 94%. Human G6PD has over 30% identity in amino acid sequence to G6PD sequences from other species. Humans also have two isoforms of a single gene coding for G6PD. Moreover, at least 168 disease-causing mutations in this gene have been discovered. These mutations are mainly missense mutations that result in amino acid substitutions, and while some of them result in G6PD deficiency, others do not seem to result in any noticeable functional differences. Some scientists have proposed that some of the genetic variation in human G6PD resulted from generations of adaptation to malarial infection. Other species experience a variation in G6PD as well. In higher plants, several isoforms of G6PDH have been reported, which are localized in the cytosol, the plastidic stroma, and peroxisomes. A modified F420-dependent (as opposed to NADP+-dependent) G6PD is found in Mycobacterium tuberculosis, and is of interest for treating tuberculosis. The bacterial G6PD found in Leuconostoc mesenteroides was shown to be reactive toward 4-hydroxynonenal, in addition to G6P.
National Commission on Terrorist Attacks Upon the United States—Official commission website List of victims September 11, 2001, Documentary Project from the U.S. Library of Congress, Memory.loc.gov September 11, 2001, Web Archive from the U.S. Library of Congress The September 11th Sourcebooks at The National Security Archive September 11 Digital Archive: Saving the Histories of September 11, 2001, from the Center for History and New Media and the American Social History Project/Center for Media and Learning The 9/11 Legacies Project, Oriental Institute, Czech Academy of Sciences, Prague 9/11 at 20: A Week of Reflection; Archived April 16, 2022, at the Wayback Machine, Quincy Institute for Responsible Statecraft September 11, 2001 collection at the Smithsonian National Museum of American History Multimedia
== Awards and honors == 2024 York U Alumni Award for Outstanding Achievement 2020 Lifetime Achievement Award in Plasma Spectrochemistry 2019 HUPO Award (Human Proteome Organization) 2014 Fellow of the American Institute for Medical and Biological Engineering 2011 University of Toronto Inventor of the Year Award for Biomedical and Life Sciences 2011 Thermo Fisher Scientific Spectroscopy Award 2004 Elsevier / Spectrochimica Acta Atomic Spectroscopy Award for the most important paper published in Spectrochimica Acta Part B in 2002 (Title: Reaction cells and collision cells for ICP-MS: a tutorial review) in co-authorship with Dmitry Bandura and Vladimir Baranov 2003 W.A.E. McBryde medal from the Canadian Chemical Society of the Chemical Institute of Canada 2001 Manning Innovation Award, Award of Distinction Dr. Scott Tanner, together with Dr. Vladimir Baranov, received the Manning Award of Distinction from the Manning Innovation Awards Foundation for the remarkable invention of the ICP-MS Dynamic Reaction Cell (Collision/reaction cell). 1999 Pittcon Editors' Awards Perkin-Elmer Sciex for their ELAN 6100 DRC (Dynamic Reaction Cell) ICP-MS system. Fellow of the Royal Society of Chemistry (UK) Fellow of the American Institute for Medical and Biological Engineering (AIMBE)
=== Scalp hair loss === Clascoterone is under development for the treatment of androgen-dependent scalp hair loss. Two phase 3 clinical trials were completed and disclosed in December 2025. The drug significantly improved hair growth in both trials. More specifically, target area hair count (TAHC) had a relative improvement of 5.39-fold (539%) in one study and of 1.68-fold (168%) in the other study, both compared to placebo. In other words, hair growth improved in both the placebo and clascoterone groups, but growth improved by about 1.7- to 5.4-fold more with clascoterone than with placebo. The actual absolute changes in hair counts in the different groups have not yet been released.
Sources: en.wikipedia.org
It is a synthetic research compound that activates REV-ERB nuclear receptors. It is not an approved drug or dietary supplement. Most information comes from cell and animal studies.
It binds REV-ERBα and REV-ERBβ and changes transcription of metabolic genes. This can affect circadian rhythm, lipid use, and mitochondrial function. The full downstream effects are still under study.
No. Some rodent studies show increased endurance, but controlled human trials are lacking. Claims about human performance are not established by published evidence.
Laboratories commonly use liquid chromatography coupled with mass spectrometry to detect SR9009. The method can identify the compound and estimate concentration in a sample. Detection limits depend on the matrix and instrument.